Nonsteroidal antiinflammatory drugs and the kidney

Czech version

Authors: J. Zadražil
Authors‘ workplace: III. interní klinika Lékařské fakulty UP a FN, Olomouc, přednosta prof. MUDr. Vlastimil Ščudla, CSc.
Published in: Vnitř Lék 2006; 52(7-8): 686-690
Category: 130th Internal Medicine Day - Rheumatology in clinical practice

Overview

Nonsteroidal antiinflammatory drugs (NSAIDs) have potentially important renal adverse effects. With regard to renal adverse effects there is no indication of significant differences between conventional NSAIDs and selective COX-2 inhibitors. Their nephrotoxicity has been well documented. Many of the renal abnormalities that are encountered as a result of NSAIDs use can be attributed to the inhibition of prostaglandins synthesis. The release of prostaglandins is particulary importent in high-risk patients, including patients with severe heart disease, liver disease, preexisting renal disease, elderly and patients with volume depletion. The common complication of NSAID use is retention of sodium and edema formation due to increased reabsorption of sodium and water in the loop of Henle and hyperkalemie due to diminished renin secretion. Nonsteroidal antiiflammatory drugs can induce two different forms of acute renal failure. Decreased prostaglandin synthesis can lead to reversible renal ischemia and hemodynamically-mediated acute renal failure. Second form of acute renal failure is acute interstitial nephritis. This type of interstitial nephritis is often accompanied by nephrotic syndrome due to minimal change disease. Nephrotic syndrome after NSAIDs treatments may be also associated with membranous nephropathy. Another complication of NSAIDs treatment is modest rise of systemic blood pressure in some hypertensive patients due to increase in renal and systemic vascular resistence. In patients consuming excessive amount of NSAIDs over a prolonged period of years papillary necrosis can occur. Exposure to large quantities of NSAIDs can probably induce in some patients chronic renal insufficiency.

Key words:
nonsteroidal antiiflammatory drugs - prostaglandins - acute renal failure - acute intestitial nephritis - nephrotic syndrome - hyperkalemia - hyponatremia - water retention - papillary necrosis - chronic renal insufficiency

Sources

1. Pirmohamed M, James S, Meakin S et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15-19.

2. FitzGerald GA. The choreography of cyclooxygenases in the kidney. J Clin Invest 2002; 110: 33-34.

3. Diaz-Gonzalez F, Gonzalez-Alvaro I, Campanero MR et al. Prevention of in vitro neutrophil-endothelial attachment through shedding of L-selectin by nonsteroidal antiinflammatory drugs. J Clin Invest 1995; 95: 1756-1765.

4. Amin AR, Vyas P, Attur M et al. The mode of action of aspirin like-drugs: Effect on inducible nitric oxide synthetase. Proc Natl Acad Sci USA 1995; 92: 1926-1930.

5. Huerta C, Castellsague J, Varas-Lorenzo C et al. Nonsteroidal antiinflammatory drugs and risk of ARF in the general population. Am J Kidney Dis 2005; 45: 531-539.

6. Horáčková M. Analgetika a ledviny. Vztah hodnocený klinickým nefrologem. Praha: Triton 2000.

7. Whelton A, Stout RL, Spilman PS et al. Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure. A prospective, randomized, crossover comparison. Ann Intern Med 1990; 112: 568-576.

8. Braden GL, O´Shea MH, Mulhern JG et al. Acute renal failure and hyperkalaemia associated with cyclooxygenase-2 inhibitors. Nephrol Dial Transplant 2004; 19: 1149-1153.

9. Perazella MA, Tray K. Selective cyclooxygenase-2 inhibitors: A pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. Am J Med 2001; 111: 64-67.

10. Baker RL, Pusey CD. The changing profile of acute tubulointerstitial nephritis. Nephrol Dial Transplant 2004; 19: 8-11.

11. Alper AB jr, Meleg-Smith S, Krane NK. Nephrotic syndrome and interstitial nephritis associated with celecoxib. Am J Kidney Dis 2002; 40: 1086-1090.

12. Esteve JB, Launay-Vacher V, Brocheriou I et al. COX-2 inhibitors and acute interstitial nephritis: Case report and review of the literature. Clin Nephrol 2005; 63: 385-389.

13. Rossert J. Drug-induced acute interstitial nephritis. Kidney Int 2001; 60: 804-817.

14. Neilson EG. Pathogenesis and therapy of interstitial nephritis. Kidney Int 1989; 35: 1257-1270.

15. Clarkson MR, Giblin L, O´Connell FP et al. Acute interstitial nephritis: Clinical features and response to corticosteroid therapy. Nephrol Dial Transplant 2004; 19: 2778-2783.

16. Warren GV, Korbet SM, Schwartz MM et al. Minimal change glomerulopathy associated with nonsteroidal antiinflammatory drugs. Am J Kidney Dis 1989; 13: 127-130.

17. Campistol JM, Galofre J, Botey A et al. Reversible membranous nephritis associated with diclofenac. Nephrol Dial Transplant 1989; 4: 393-395.

18. Radford MG, Holley KE, Grande JP et al. Reversible membranous nephropathy associated with the use of nonsteroidal antiinflammatory drugs. JAMA 1996; 276: 466-469.

19. Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int 1993; 44: 643-653.

20. Kramer HJ, Glanzer K, Dusing R. Role of prostaglandins in the regulation of renal water excretion. Kidney Int 1981; 19: 851-859.

21. Hebert RL, Carmosino M, Saito O et al. Characterization of rabbit kidney prostaglandin F (2 alpha) receptor exhibiting G(i)-restricted signaling that inhibits water absorption in the collecting duct. J Biol Chem 2005; 280: 35028-35037.

22. Satoh T, Cohen HT, Katz AI. Intracellular signalling in the regulation of renal Na-K-ATPase. Role of cyclic AMP and phospholipase A2. J Clin Invest 1992; 89: 1496-1500.

23. Gunning ME, Brady HR, Otuechere G et al. Atrial natriuretic peptide (31-67) inhibits Na+ transport in rabbit inner medullary collecting duct. Role of prostaglandin E2. J Clin Invest 1992; 89: 1411-1417.

24. Oates JA, FitzGerald GA, Branch RA et al. Clinical implications of prostaglandin and thromboxane A2 formation. N Engl J Med 1988; 319: 761-767.

25. Brater DC. Anti-inflammatory agents and renal function. Semin Arthritis Rheum 2002; 32 (Suppl 1): 33-42.

26. Clark BA, Shannon RP, Rosa RM et al. Increased susceptibility to thiazide-induced hyponatremia in the elderly. J Am Soc Nephrol 1994; 5: 1106-1111.

27. Weir MR. Renal effects of nonselective NSAIDs and coxibs. Cleve Clin J Med 2002; 69 (Suppl 1): 153-158.

28. Fu Q, Zhang R, Witkowski S et al. Persistent sympathetic activation during chronic antihypertensive therapy: a potential mechanism for long term morbidity? Hypertension 2005; 45: 513-521.

29. Pope JE. Hypertension, NSAID, and lessons learned. J Rheumatol 2004; 31: 1143-1151.

30. Sowers JR, White WB, Pitt B et al. The effects of cyclooxygenase-2 inhibitors and nonsteroidal antiinflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005; 165: 161-168.

31. Fogari R, Zoppi A, Carretta R et al. Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: A multicentre study. J Hypertens 2002; 20: 1007-1014.

32. Aw TJ, Haas SJ, Liew D et al. Metaanalysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005; 165: 490-496.

33. Klassen DK, Jane LH, Young DY et al. Assessment of blood pressure during naproxen therapy in hypertensive patient treated with nicardipine. Am J Hypertens 1995; 8: 146-153.

34. Bennett WM, Porter GA. Analgesic nephropathy and the use of nonsteroidal antiiflammatory drugs in renal patients: New insights. J Nephrol 1998; 11: 70-75.

35. Akhund L, Quinet RJ, Ishaq S. Celecoxib - related renal papillary necrosis. Arch Intern Med 2003; 163: 114-115.

36. Safirstein R. Gene expression in nephrotoxic and ischemic acute renal failure. J Am Soc Nephrol 1994; 4: 1387-1395.

37. Gault MH, Garrett BJ. Analgesic nephropathy. Am J Kidney Dis 1998; 32: 351-360.

38. Segasothy M, Samad S, Zulfigar A et al. Chronic renal disease and papillary necrosis associated with the long-term use of nonsteroidal anti-inflammatory drugs as the sole or predominant analgesic. Am J Kidney Dis 1994; 24: 17-24.

39. Bennett WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal antiinflammatory drugs: Summary and recommendations. Am J Kidney Dis 1996; 28 (Suppl 1): 56-62.

40. Kurth T, Glynn RJ, Walker AM et al. Analgesic use and change in kidney function in apparently healthy men. Am J. Kidny Dis 2003; 42: 234-244.

41. De Broe ME, Elsevier MM. Analgesic nephropathy. N Engl J Med 1998; 338: 446-452.

42. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nosteroidal antiiflammatory drugs. N Engl J Med 1994; 331: 1675-1679.

43. Cheng HF, Harris RC. Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. Curr Pharm Des 2005, 11: 1795-1804.